[VIRTUAL] Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A

[VIRTUAL] Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics

[VIRTUAL] 4-Year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs. Docetaxel in 2L+ NSCLC

[VIRTUAL] Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

[VIRTUAL] Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1

[VIRTUAL] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First‑line Treatment for Advanced Squamous Non‑Small Cell Lung Cancer

[VIRTUAL] Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study

[VIRTUAL] Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study

[VIRTUAL] Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study

[VIRTUAL] KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC

[VIRTUAL] Systemic and Intracranial Efficacy of Brigatinib vs.Crizotinib: Updated Results from the ALTA-1L Trial

[VIRTUAL] Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial

[VIRTUAL] Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders

[VIRTUAL] Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy

[VIRTUAL] Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial